Alibaba
BABA
Micron Technology
MU
NVIDIA
NVDA
Cisco
CSCO
Netflix
NFLX
US Stock MarketDetailed Quotes
PLRZ Polyrizon
- 1.126
- +0.006+0.57%
Close Feb 14 16:00 ET
- 1.126
- 0.0000.00%
Post 20:01 ET
4.72MMarket Cap-4.27P/E (TTM)
1.200High1.066Low58.29KVolume1.120Open1.120Pre Close65.33KTurnover7.22%Turnover RatioLossP/E (Static)4.19MShares4.80052wk High-187.73P/B909.78KFloat Cap0.77052wk Low--Dividend TTM807.69KShs Float4.800Historical High--Div YieldTTM11.99%Amplitude0.770Historical Low1.120Avg Price1Lot Size
Trending Stocks
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Polyrizon Stock Forum
Polyrizon Announces Filing of Divisional Patent Application for Its Innovative Trap & Target™ (T&T) Intranasal Drug Delivery Platform
Thursday, 30th January at 5:55 am
Raanana, Israel, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ: PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the filing of a divisional patent application with the Israel Patent Offi...
The divisional patent application for Polyrizon's Trap & Target platform represents a strategic move to strengthen their IP position in the rapidly growing intranasal drug delivery market, currently valued at over $50 billion globally. The technology's versatility in accommodating various drug types positions it as a potential game-changer for both existing and new therapeutic applications.
The platform's technical advantages are particula...
Game-Changing Nasal Drug Tech Could Transform Treatment of Seizures and Overdoses
With the global nasal spray market projected to reach over $23 billion by 2029, driven by increasing demand for innovative and effective solutions, Polyrizon is proud to take this step forward in advancing our PL-14 allergy blocker toward clinical trial," said Tomer Izraeli, CEO of Polyrizon. "By collaborating with Eurofins CDMO Amatsiaquitain...
Polyrizon Commences GMP Manufacturing Preliminary Process for its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial
Thursday, 23rd January at 6:40 am
Eurofins CDMO Amatsiaquitaine S.A.S., the GMP manufacturer, to support Polyrizon in future commercialization efforts
Raanana, Israel, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasa...
• Clinical trials not yet started, pending 2025 initiation
• No current revenue generation as still in development stage
• Product efficacy and safety yet to be proven in clinical trials
Polyrizon Commences Gmp Manufacturing Preliminary Process for Its Pl-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial
No comment yet